|
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $3.03 | - | - |
| Q1'26 | $2.36 | $2.70 | +14.4% |
| Q4'25 | $2.47 | $4.53 | +83.1% |
| Q3'25 | $3.22 | $3.40 | +5.5% |
| Q2'25 | $2.94 | $2.95 | +0.3% |
| Q1'25 | $2.22 | $2.25 | +1.2% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $1.6B | - | - |
| Q1'26 | $1.2B | $1.3B | +4.3% |
| Q4'25 | $712M | $932M | +31.0% |
| Q3'25 | - | $800M | - |
| Q2'25 | - | $771M | - |
| Q1'25 | - | $662M | - |
Market Data
WAT is currently trading at $333.21, giving Waters Corporation a market cap of 32.88B and a P/E ratio of 73.2. Today's range spans $328.21–$333.94, with shares opening at $328.21 and moving up $0.08 (0.0%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 71/100.
Over the past year WAT has traded between $275.05 and $414.15 - the current price is +21.1% off the 52-week low and -19.5% from the high.
Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and WAT (32.88B market cap) with a BUY read (77/100) and bullish sentiment (71/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 73.2. Price: $333.21 (in the lower half of its 52-week range in $275.05–$414.15). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.
The combination of a BUY signal (77/100) and bullish news sentiment (71/100) puts WAT on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 32.88B in Healthcare market cap without immediately moving the stock. At $333.21 (in the lower half of its 52-week range in the $275.05–$414.15 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).